%0 Journal Article
%T Two cases of typical HUS in adults treated with an anti-C5 monoclonal antibody: a new perspective?
%A Stambolliu E
%A Giannou P
%A Nomikou E
%A Aggelis G
%A Petras D
%J J Nephrol
%V 0
%N 0
%D 2024 Jul 29
%M 39073701
%F 4.393
%R 10.1007/s40620-024-02034-2
%X Hemolytic uremic syndrome (HUS) is a rare clinical entity, especially in adults. In its typical form the causative factor that triggers the cascade of immunologic and inflammatory events is a Shiga toxin-producing pathogen, found in the patient's stool. Renal and neurologic involvement usually prevails and requires immediate care. Regarding this potentially life-threatening condition, little is known and the mainstay is supportive care. However, some interesting evidence has come up about the use of eculizumab, an anti-C5 monoclonal antibody, mainly in pediatric patients with typical HUS. Herein, we present two cases with typical HUS caused by two different strains of Escherichia coli (Shiga toxin-producing enterohemorrhagic and enteropathogenic) who were both treated effectively with anti-C5 monoclonal antibodies (eculizumab and ravulizumab).